summary: This open label study of Campath-1-H showed that it is very effective at preventing relapses in the small minority of patients with relapsing-remitting MS who have early aggressive disease. However there was a higher risk of side effects than with conventional treatments.

authors: Hirst CL, Pace A, Pickersgill TP, Jones R, McLean BN, Zajicek JP, Scolding NJ, Robertson NP.

source: J Neurol. 2008 Feb 20 [Epub ahead of print]

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: